Etuvetidigene autotemcel
Etuvetidigene autotemcel is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including WASKYRA. Available dosage form: injection.
Drug details
- Generic Name
- Etuvetidigene autotemcel
- Brand Names
- WASKYRA
- Application Number
- BLA125846
- Sponsor
- Fondazione Telethon ETS
- NDC Codes
- 2
- Dosage Forms
- INJECTION
- Routes
- INTRAVENOUS
- Active Ingredients
- ETUVETIDIGENE AUTOTEMCEL
Indications and Usage
1 INDICATIONS AND USAGE WASKYRA ® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available. WASKYRA ® is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related hematopoietic stem cell donor is available. ( 1 )